Gries Financial LLC Purchases 110 Shares of Danaher Co. (NYSE:DHR)

Gries Financial LLC lifted its position in shares of Danaher Co. (NYSE:DHR) by 11.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,064 shares of the conglomerate’s stock after purchasing an additional 110 shares during the quarter. Gries Financial LLC’s holdings in Danaher were worth $244,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Fort Pitt Capital Group LLC grew its stake in Danaher by 3.2% in the third quarter. Fort Pitt Capital Group LLC now owns 238,092 shares of the conglomerate’s stock valued at $66,194,000 after acquiring an additional 7,421 shares during the period. Good Life Advisors LLC bought a new position in shares of Danaher during the 3rd quarter valued at about $217,000. ORG Partners LLC increased its stake in Danaher by 1,212.8% during the 4th quarter. ORG Partners LLC now owns 2,770 shares of the conglomerate’s stock worth $636,000 after purchasing an additional 2,559 shares in the last quarter. Harvest Portfolios Group Inc. raised its holdings in Danaher by 1.2% during the 3rd quarter. Harvest Portfolios Group Inc. now owns 202,263 shares of the conglomerate’s stock worth $56,233,000 after buying an additional 2,465 shares during the period. Finally, Stifel Financial Corp lifted its stake in Danaher by 1.3% in the third quarter. Stifel Financial Corp now owns 847,348 shares of the conglomerate’s stock valued at $235,583,000 after buying an additional 11,216 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Down 0.3 %

DHR opened at $223.16 on Friday. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The stock’s fifty day simple moving average is $235.89 and its 200 day simple moving average is $253.45. Danaher Co. has a 1-year low of $221.34 and a 1-year high of $281.70. The stock has a market cap of $161.19 billion, a PE ratio of 42.59, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. During the same quarter in the previous year, the firm posted $2.09 earnings per share. As a group, research analysts expect that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Friday, December 27th will be paid a $0.27 dividend. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a yield of 0.48%. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of research analyst reports. Royal Bank of Canada restated an “outperform” rating and set a $277.00 price objective (down from $299.00) on shares of Danaher in a report on Thursday. KeyCorp boosted their price target on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. Wells Fargo & Company decreased their price objective on Danaher from $280.00 to $240.00 and set an “equal weight” rating for the company in a report on Thursday. UBS Group cut their target price on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research note on Wednesday, October 23rd. Finally, Barclays decreased their price target on shares of Danaher from $275.00 to $240.00 and set an “equal weight” rating for the company in a research note on Thursday. Six research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.